EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Gender‐affirming hormone therapy for transgender and gender‐diverse adults in Australia

Brendan J Nolan iD, Ada S Cheung iD

Internal Medicine Journal · 2024-09 · 54 (9) · 1450-1457

DOI: 10.1111/imj.16413 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Internal Medicine Journal, online erschienen am 26.07.2024. Verfasst von Brendan J Nolan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Queensland, Australia. Hauptthemen laut MEDLINE: Transgender Persons, Testosterone, Estradiol. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Health and Medical Research Council, RACP Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gender‐affirming hormone therapy (GAHT) is used by many transgender and gender‐diverse adults to align physical characteristics with their gender identity, reduce gender incongruence and improve psychological functioning. This narrative review provides an overview of the initiation and monitoring of GAHT in an Australian context. Trans individuals treated with testosterone typically receive standard testosterone doses and formulations recommended for cisgender men, whereas those receiving estradiol GAHT are typically treated with estradiol in combination with an anti‐androgen in those without orchidectomy. Proactive monitoring and mitigation of cardiovascular risk factors is pertinent in all transgender and gender‐diverse adults and bone health is an important consideration in those using estradiol GAHT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Transgender PersonsTestosteroneEstradiolHumansAustraliaMaleFemaleAdultHormone Replacement TherapyAndrogen AntagonistsGender IdentityGender DysphoriaTranssexualism

Stichwörter der Autor:innen

estradiolgender‐affirming hormone therapytestosteronetransgender

Substanzen

TestosteroneEstradiolAndrogen Antagonists

Autor:innen und Institutionen

  • Department of Diabetes and Endocrinology, Princess Alexandra Hospital, Brisbane, Queensland, Australia.
  • Trans Health Research Group, Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia.
  • Equinox Gender Diverse Clinic, Thorne Harbour Health, Melbourne, Victoria, Australia.
  • Department of Endocrinology, Austin Health, Melbourne, Victoria, Australia.

ORCID-Profile: Brendan J Nolan, Ada S Cheung

Förderung

  • National Health and Medical Research Council
  • RACP Foundation

Zitieren

APA

Nolan, B. J., & Cheung, A. S. (2024). Gender‐affirming hormone therapy for transgender and gender‐diverse adults in Australia. Internal Medicine Journal, 54(9), 1450-1457. https://doi.org/10.1111/imj.16413

Vancouver

Nolan BJ, Cheung AS. Gender‐affirming hormone therapy for transgender and gender‐diverse adults in Australia. Internal Medicine Journal. 2024;54(9):1450-1457. doi:10.1111/imj.16413

BibTeX
@article{Nolan2024,
  author = {Nolan, Brendan J and Cheung, Ada S},
  title = {Gender‐affirming hormone therapy for transgender and gender‐diverse adults in Australia},
  journal = {Internal Medicine Journal},
  year = {2024},
  volume = {54},
  number = {9},
  pages = {1450--1457},
  doi = {10.1111/imj.16413}
}
Kostenlos starten →